Kentucky Ozempic/Wegovy Lawyers file Stomach Injury Claims, KY Mounjaro/Rybelsus lawsuits
Kentucky Ozempic & Wegovy Lawyers for Gastroparesis Claims
Louisville · Bowling Green · Owensboro · Covington
Call Now: (888) 510-9258
Hotline Open 24 Hours
Our Kentucky GLP-1 lawyers represent diabetes and weight loss patients in stomach injury lawsuits. Kentucky Ozempic/Wegovy lawsuits claim these and similar semaglutide drugs put patients at undue risk of harm.
As such, Kentucky GLP-1 patients hospitalized for a stomach injury may be eligible for a cash settlement.
Ozempic · Wegovy · Mounjaro · Rybelsus · Victoza · Saxenda
Our team of Kentucky Mounjaro/Rybelsus lawyers have represented thousands of victims of diabetes and weight loss drugs. In doing so, we have recovered millions of dollars in settlement funds on their behalf.
However, we only pursue compensation from GLP-1 drug manufacturers and their affiliates, and do not file claims against our clients’ doctors or hospitals.
No Legal Fee Unless You Obtain a Settlement
While compensation may be available to qualified semaglutide claimants, victims are urged to act promptly. The No. 1 thing a Kentucky GLP-1 patient can do to pursue compensation for gastroparesis is file a claim within the Statute of Limitations time period. Click here to view the latest information on the pending Multi-District Litigation.
Our Kentucky Ozempic/Wegovy lawyers are available to review claims now. We offer a free case evaluation to confirm usage of a qualified GLP-1 medication and diagnosis of a related gastric injury. Further, we never charge a legal fee unless a financial recovery is obtained for our client.
Contact our Kentucky Ozempic/GLP-1 lawyers today.
Kentucky Ozempic/Wegovy Stomach Paralysis Claims
Doctors frequently prescribe GLP-1 drugs when lifestyle changes and other diabetes medications are unable to control blood sugar levels. In addition, GLP-1s are effective for weight loss and lowering the risk of cardiovascular events.
However, Kentucky semaglutide lawyers allege the manufacturers of Ozempic, Wegovy, Mounjaro and Rybelsus failed to protect users from gastroparesis and other serious stomach injuries. This failure to warn could have resulted in hospitalization. Unfortunately, many GLP-1 patients have required invasive stomach operations. As can only be expected, they have faced challenging recoveries. A timely GLP-1 claim can secure funds to pay medical expenses and compensate for needless pain and suffering.
Injuries Associated with GLP-1 Medication
- Gastroparesis
- Stomach paralysis
- Gastric obstruction
- Delayed gastric implant
Kentucky Mounjaro/Rybelsus Lawyers for Stomach Injury Claims
Authorities in Kentucky have recognized stomach injuries associated with the use of GLP-1 antagonist drugs among weight loss and diabetes patients. GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone in the human body. It plays a crucial role in the regulation of blood sugar levels. Medications based on GLP-1, such as Victoza or Saxenda, are typically prescribed to Kentucky residents with type 2 diabetes to improve blood sugar control. These semaglutide medications are usually administered as a once-weekly injection under the skin, and have several benefits.
Intended Benefits of GLP-1 Drugs
- Stimulates the release of insulin
- Reduces the amount of glucose produced by the liver
- Slows down the rate at which the stomach empties
Kentucky Mounjaro/Rybelsus lawyers note GLP-1 receptor agonists have shown efficacy in improving glycemic control by reducing blood sugar levels. They stimulate insulin secretion and inhibit glucagon release, helping regulate blood glucose. Further, certain GLP-1 drugs have been associated with weight loss and weight management. These effects have been particularly beneficial for type 2 diabetics who also struggle with obesity.
In addition to insulin regulation, many GLP-1 drugs have undergone cardiovascular trials to assess their impact on major cardiovascular events. Some trials have shown cardiovascular benefits, such as a reduction in the risk of heart attack.
Treatment of Type 2 Diabetes and Obesity with GLP-1 Injections
This exciting new line of treatment has been paramount for diabetes management and obesity. However, Kentucky GLP-1 lawsuits have raised concerns that Ozempic, along with Wegovy, Mounjaro and Rybelsus, have increasingly become associated with gastroparesis, stomach paralysis and gastric obstruction. As such, KY GLP-1 attorneys have begun an investigation of semaglutide drug warning label requirements.
Semaglutide Side Effects in Kentucky GLP-1 Patients
- Nausea: Some individuals may experience nausea, especially when starting Ozempic or Wegovy. This side effect often improves over time.
- Diarrhea: Diarrhea is a possible side effect, and it may occur in some people.
- Vomiting: Similar to nausea, vomiting may occur, particularly in the initial stages of treatment.
- Constipation: On the other hand, some individuals may experience constipation.
- Abdominal Pain: Abdominal pain or discomfort may be reported by some individuals.
- Headache: Headaches are a common side effect but are generally mild.
- Fatigue: Some people may experience fatigue or tiredness.
- Dizziness: Dizziness is a potential side effect.
- Decreased Appetite: Mounjaro and Rybelsus can lead to a reduction in appetite, contributing to weight loss in some individuals.
- Injection Site Reactions: Since Ozempic and Wegovy are administered by injection, there may be reactions at the injection site, such as redness or itching.
- Hypoglycemia (Low Blood Sugar): When used with certain antidiabetic medications, Wegovy may increase the risk of hypoglycemia.
Click here to view FDA drug safety information.
Novo Nordisk sued over Kentucky semaglutide sales
Kentucky Ozempic, Wegovy, Rybelsus lawsuits have been filed against GLP-1 drug manufacturer Novo Nordisk and affiliates.
Since its establishment in Denmark in 1923, Novo Nordisk has emerged as a leading player in the global pharmaceutical industry. Kentucky Ozempic/Rybelsus lawyers note their work is primarily focused on diabetes care, as well as other chronic conditions. The company operates globally, with offices and production facilities in various countries around the world.
While Novo Nordisk manufactures a broad range of products including insulin, their GLP-1 receptor agonists have become increasingly popular.
KY Victoza/Saxenda Lawyers Target Novo Dordisk GLP-1 Drugs
- Ozempic (injection)
- Wegovy (injection)
- Rybelsus (tablet form)
- Victoza (injection)
- Saxenda (injection)
Despite the benefits of these semaglutide drugs, several side effects are associated with the medication. Furthermore, many people have reported adverse events related to Ozempic. Health records often show symptoms beginning with stomach pain and worsening to the point of emergency room care.
Beyond the physical discomfort, these injuries can significantly impact the lives of those affected. Therefore, many Kentucky diabetes and weight loss patients have found it necessary to assert their rights in court.
Kentucky Mounjaro Lawyers Suing Eli Lilly Co. for Gastric Injuries
Mounjaro is manufactured by Eli Lilly and Company. Colonel Eli Lilly founded this global pharmaceutical company in Indianapolis in 1876, and it still has its headquarters in Indianapolis, Indiana.
Eli Lilly has made significant contributions in various therapeutic areas such as diabetes, oncology, neuroscience, immunology, and cardiovascular diseases. The company has developed and markets several well-known medications, including insulin products like Humalog and Humulin, antidepressant Prozac, cancer drug Alimta, and others.
Kentucky Gastroparesis Lawsuits for Mounjaro/Ozempic Hospitalization
Gastroparesis is a digestive disorder where the stomach muscles fail to function properly, hindering the timely emptying of food. This condition can result in a range of symptoms affecting the digestive system.
Symptoms of GLP-1 Induced Gastroparesis
- Nausea and Vomiting: Persistent feelings of nausea and vomiting may occur, especially after eating.
- Abdominal Pain: Individuals with gastroparesis may experience discomfort or pain in the abdominal region.
- Bloating: The stomach may feel bloated, contributing to feelings of fullness.
- Heartburn or Acid Reflux: Gastroparesis can lead to the regurgitation of stomach contents, causing heartburn.
- Fluctuating Blood Sugar Levels: For individuals with diabetes, gastroparesis can impact blood sugar control due to delayed digestion.
If you took a GLP-1 medication and were hospitalized for gastroparesis, stomach paralysis or gastric obstruction, you may be entitled to compensation.
Victoza/Saxenda Intestinal Injury Diagnosed in Kentucky?
Understanding the role of GLP-1 is crucial in the context of diabetes management. Medications can enhance insulin secretion, reduce blood sugar levels, and aid in weight management by targeting this hormone.
Kentucky Mounjaro/Rybelsus lawyers have taken a keen interest in intestinal injuries. After all, the cells of the small intestine produce GLP-1 in response to the presence of food.
The primary function of GLP-1 is to stimulate the release of insulin from the pancreas. Insulin is a hormone that helps regulate blood sugar by facilitating the uptake of glucose by cells. In addition, GLP-1 inhibits the release of glucagon, another pancreatic hormone. Glucagon typically raises blood sugar levels by prompting the liver to release glucose into the bloodstream. Therefore, inhibiting glucagon helps lower blood sugar levels.
Kentucky Victoza/Saxenda lawyers note GLP-1 slows down the rate at which the stomach empties its contents into the small intestine. This helps regulate the digestion and absorption of nutrients. GLP-1 has an impact on appetite regulation. It promotes a feeling of fullness (satiety), leading to reduced food intake.
Medications known as GLP-1 receptor agonists, such as semaglutide, exenatide, and liraglutide, mimic the action of GLP-1. Doctors use these drugs to treat type 2 diabetes and, in some cases, to manage weight. KY Ozempic, Wegovy, Mounjaro and Rybelsus lawsuits have now highlighted the gastroparesis safety concerns associated with the drug.
Half-life timeframes associated with GLP-1 in the bloodstream are relatively short. An enzyme called dipeptidyl peptidase-4 (DPP-4) rapidly degrades it. This characteristic led to the development of medications that either mimic GLP-1 (GLP-1 receptor agonists) or inhibit the enzyme DPP-4 (DPP-4 inhibitors) to prolong the action of endogenous GLP-1.
We file Ozempic/GLP-1 claims in the State of Kentucky and across the United States.
- Louisville, KY
- Jefferson County, KY
- Bowling Green, KY
- Owensboro, KY
- Covington, KY
- Richmond, KY
- Georgetown, KY
- Florence, KY
- Nicholasville, KY
- Hopkinsville, KY
- Elizabethtown, KY
Call or email our Kentucky Ozempic/Wegovy lawyers now.